{"id":76381,"date":"2026-08-24T12:04:26","date_gmt":"2026-08-24T04:04:26","guid":{"rendered":"https:\/\/flcube.com\/?p=76381"},"modified":"2026-08-24T12:04:27","modified_gmt":"2026-08-24T04:04:27","slug":"leads-biolabs-files-nda-for-opamtistomig-in-ep-nec-worlds-first-4-1bb-bispecific-nears-potential-first-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76381","title":{"rendered":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#8217;s First 4-1BB Bispecific Nears Potential First Approval"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9887:HKG\">HKG: 9887<\/a>) announced that it has submitted a <strong>New Drug Application (NDA)<\/strong> to China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>opamtistomig (LBL\u2011024)<\/strong> as a <strong>monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC)<\/strong> \u2014 a filing that could produce the <strong>first approved drug for this rare, aggressive cancer<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Submission Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Opamtistomig (LBL\u2011024)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>Monotherapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC)<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887)<\/td><\/tr><tr><td><strong>Submission Date<\/strong><\/td><td>21 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Bispecific antibody targeting <strong>PD\u2011L1<\/strong> and the costimulatory receptor <strong>4\u20111BB<\/strong><\/li>\n\n\n\n<li><strong>First-in-Class Status:<\/strong> The <strong>world&#8217;s first molecule targeting 4\u20111BB to reach the single\u2011arm pivotal clinical trial stage<\/strong><\/li>\n\n\n\n<li><strong>Pioneering Potential:<\/strong> Has the potential to become the <strong>first approved drug for the treatment of EP\u2011NEC<\/strong>, a disease with no targeted therapy currently available<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-designations-four-major-accolades\" class=\"wp-block-heading\">Regulatory Designations \u2013 Four Major Accolades<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Designation<\/th><th>Agency<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>Breakthrough Therapy Designation<\/strong><\/td><td>NMPA Center for Drug Evaluation (CDE)<\/td><td>October 2024<\/td><\/tr><tr><td><strong>Orphan Drug Designation<\/strong><\/td><td>U.S. FDA<\/td><td>November 2024<\/td><\/tr><tr><td><strong>Fast Track Designation<\/strong><\/td><td>U.S. FDA<\/td><td>January 2026<\/td><\/tr><tr><td><strong>Orphan Drug Designation<\/strong><\/td><td>European Union<\/td><td>January 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-to-File in an Empty Category:<\/strong> With no approved therapy for EP\u2011NEC, an NDA acceptance \u2014 and eventual approval \u2014 would establish opamtistomig as the sole targeted option in a disease where treatment today relies on chemotherapy with limited durable benefit.<\/li>\n\n\n\n<li><strong>Novel Immunotherapy Mechanism:<\/strong> As the first 4\u20111BB\u2011targeting molecule to reach pivotal stage globally, opamtistomig validates a costimulatory approach that complements PD\u2011L1 blockade \u2014 with potential applicability well beyond EP\u2011NEC if the platform proves durable.<\/li>\n\n\n\n<li><strong>Global Regulatory Momentum:<\/strong> Four premium designations across the NMPA, FDA and EU within roughly 15 months signal alignment among major regulators on the drug&#8217;s unmet-need value, supporting potential filings in the U.S. and Europe alongside China.<\/li>\n\n\n\n<li><strong>Next Milestones:<\/strong> Investors will watch for NDA acceptance by the CDE, the timeline to approval under Breakthrough Therapy pathways, and subsequent U.S.\/EU regulatory submissions leveraging Fast Track and Orphan Drug status.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory review, approval timelines and commercial potential of opamtistomig (LBL\u2011024). Actual results may differ due to risks including CDE review outcomes, confirmatory data requirements, and competitive developments in neuroendocrine tumor therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100349_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082100349_c.\"><\/object><a id=\"wp-block-file--media-281aeb59-7db2-4264-b561-93dd73a29231\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100349_c.pdf\">2026082100349_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082100349_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-281aeb59-7db2-4264-b561-93dd73a29231\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,1974,38],"class_list":["post-76381","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-leads-biolabs","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#039;s First 4-1BB Bispecific Nears Potential First Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China&#039;s National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76381\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#039;s First 4-1BB Bispecific Nears Potential First Approval\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China&#039;s National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76381\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T04:04:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-24T04:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#8217;s First 4-1BB Bispecific Nears Potential First Approval\",\"datePublished\":\"2026-08-24T04:04:26+00:00\",\"dateModified\":\"2026-08-24T04:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Leads Biolabs\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76381#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76381\",\"name\":\"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World's First 4-1BB Bispecific Nears Potential First Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-24T04:04:26+00:00\",\"dateModified\":\"2026-08-24T04:04:27+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76381\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76381#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#8217;s First 4-1BB Bispecific Nears Potential First Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World's First 4-1BB Bispecific Nears Potential First Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76381","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World's First 4-1BB Bispecific Nears Potential First Approval","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.","og_url":"https:\/\/flcube.com\/?p=76381","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-24T04:04:26+00:00","article_modified_time":"2026-08-24T04:04:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76381#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76381"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#8217;s First 4-1BB Bispecific Nears Potential First Approval","datePublished":"2026-08-24T04:04:26+00:00","dateModified":"2026-08-24T04:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76381"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Leads Biolabs","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76381#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76381","url":"https:\/\/flcube.com\/?p=76381","name":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World's First 4-1BB Bispecific Nears Potential First Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-24T04:04:26+00:00","dateModified":"2026-08-24T04:04:27+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for opamtistomig (LBL\u2011024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP\u2011NEC) \u2014 a filing that could produce the first approved drug for this rare, aggressive cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76381#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76381"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76381#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs Files NDA for Opamtistomig in EP-NEC \u2014 World&#8217;s First 4-1BB Bispecific Nears Potential First Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76381"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76381\/revisions"}],"predecessor-version":[{"id":76385,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76381\/revisions\/76385"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}